| 2026-05-07 |
详情>>
股本变动：
变动后总股本824.43万股
|
| 2026-05-07 |
详情>>
业绩披露：
2026年一季报每股收益-0.54美元,归母净利润-367.19万美元,同比去年增长-96.9%
|
| 2026-04-21 |
股东大会：
将于2026-06-03召开股东大会
会议内容 ▼▲
- 1.To elect four directors to our Board of Directors, to serve until the next annual meeting and until their successors are duly elected and qualified;
2.To ratify the appointment of Tanner LLC as the independent registered public accounting firm of Lipocine for the year ending December 31, 2026;
3.To adopt, on an advisory basis, a non-binding resolution approving the compensation of the Company’s named executive officers, as described in the Proxy Statement under “Executive Compensation”;
4.To approve an amendment and restatement of our Fifth Amended and Restated 2014 Stock and Incentive Plan to (I) increase the annual individual award limits thereunder from 25,000 to 100,000 and (II) increase the authorized number of shares of common stock issuable under all awards granted under such plan from 600,000 to 1,000,000 shares;
5.To approve the adjournment of the Annual Meeting, if necessary, to continue to solicit votes in favor of the foregoing proposals;
6.To conduct any other business properly brought before the Annual Meeting and any adjournment or postponement thereof.
|
| 2026-04-07 |
详情>>
内部人交易：
Higuchi John W.股份增加40000.00股
|
| 2026-04-02 |
复牌提示：
2026-04-02 07:55:00 停牌，复牌日期 2026-04-02 08:30:00
|
| 2026-03-10 |
详情>>
业绩披露：
2025年年报每股收益-1.77美元,归母净利润-962.75万美元,同比去年增长-115371.85%
|
| 2025-11-06 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-1.35美元,归母净利润-725.74万美元,同比去年增长-309.14%
|
| 2025-08-05 |
详情>>
业绩披露：
2025年中报每股收益-0.76美元,归母净利润-407.06万美元,同比去年增长-1014.77%
|
| 2025-05-08 |
详情>>
业绩披露：
2025年一季报每股收益-0.35美元,归母净利润-186.49万美元,同比去年增长-153.08%
|
| 2025-04-22 |
股东大会：
将于2025-06-04召开股东大会
会议内容 ▼▲
- 1.To elect six directors to our Board of Directors, to serve until the next annual meeting or until their successors are duly elected and qualified;
2.To ratify the appointment of Tanner LLC as the independent registered public accounting firm of Lipocine for the year ending December 31, 2025;
3.To adopt, on an advisory basis, a non-binding resolution approving the compensation of the Company’s named executive officers, as described in the Proxy Statement under “Executive Compensation”;
4.To approve an amendment to our Amended and Restated Certificate of Incorporation to reduce the number of authorized shares of the Company’s Common Stock (the “Authorized Share Decrease”) from 200,000,000 shares to 75,000,000 shares (the “Authorized Share Decrease Proposal”);
5.To approve the adjournment of the Annual Meeting, if necessary, to continue to solicit votes in favor of the foregoing proposals;
6.To conduct any other business properly brought before the Annual Meeting and any adjournment or postponement thereof.
|
| 2025-03-13 |
详情>>
业绩披露：
2024年年报每股收益0.00美元,归母净利润8352.00美元,同比去年增长100.05%
|
| 2024-11-07 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.33美元,归母净利润-177.38万美元,同比去年增长87.39%
|
| 2024-08-08 |
详情>>
业绩披露：
2024年中报每股收益0.08美元,归母净利润44.50万美元,同比去年增长106.00%
|
| 2024-05-09 |
详情>>
业绩披露：
2024年一季报每股收益0.66美元,归母净利润351.36万美元,同比去年增长190.78%
|
| 2024-04-23 |
股东大会：
将于2024-06-05召开股东大会
会议内容 ▼▲
- 1.To elect six (6) directors to our Board of Directors, to serve until the next annual meeting or until their successors are duly elected and qualified.
2.To ratify the appointment of Tanner LLC as the independent registered public accounting firm of Lipocine for the year ending December 31, 2024.
3.To adopt, on an advisory basis, a non-binding resolution approving the compensation of the Company’s named executive officers, as described in the Proxy Statement under “Executive Compensation”.
4.To vote, on an advisory basis, on the frequency of future advisory votes to approve the compensation of the Company’s named executive officers.
5.To approve an amendment and restatement of our Fourth Amended and Restated 2014 Stock and Incentive Plan to increase the annual individual award limits thereunder from 336,582 shares to 600,000 shares.
6.To conduct any other business properly brought before the Annual Meeting and any adjournment or postponement thereof.
|
| 2024-03-07 |
详情>>
业绩披露：
2023年年报每股收益-3.1美元,归母净利润-1635.22万美元,同比去年增长-51.99%
|
| 2023-05-12 |
详情>>
拆分方案：
每17.0000合并分成1.0000股
|
| 2023-03-27 |
股东大会：
将于2023-05-10召开股东大会
会议内容 ▼▲
- 1.To elect six (6) directors to our Board of Directors, to serve until the next annual meeting or until their successors are duly elected and qualified;
2.To ratify the appointment of Tanner LLC as the independent registered public accounting firm of Lipocine for the year ending December 31, 2023;
3.To adopt, on an advisory basis, a non-binding resolution approving the compensation of the Company’s named executive officers, as described in the Proxy Statement under “Executive Compensation”;
4.To approve an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) to effect a reverse stock split at a ratio not less than 1-for-5 and not greater than 1-for-20, with the exact ratio to be set within that range at the discretion of our Board of Directors without further approval or authorization of our stockholders;
5.To approve the adjournment of the Annual Meeting, if necessary, to continue to solicit votes in favor of the foregoing proposals;
6.To conduct any other business properly brought before the Annual Meeting and any adjournment or postponement thereof.
|
| 2022-04-22 |
股东大会：
将于2022-06-08召开股东大会
会议内容 ▼▲
- 1.To elect six (6) directors to our Board of Directors, to serve until the next annual meeting and until their successors are duly elected and qualified;
2.To ratify the appointment of Tanner LLC as the independent registered public accounting firm of Lipocine for the year ending December 31, 2022;
3.To adopt, on an advisory basis, a non-binding resolution approving the compensation of the Company’s named executive officers, as described in the Proxy Statement under “Executive Compensation”;
4.To approve an amendment to the Amended and Restated Certificate of Incorporation of the Company to increase the number of authorized shares of common stock from 100,000,000 to 200,000,000 shares;
5.To approve the adjournment of the Annual Meeting, if necessary, to continue to solicit votes in favor of the foregoing proposals;
6.To conduct any other business properly brought before the Annual Meeting and any adjournment or postponement thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-27 |
股东大会：
将于2021-06-09召开股东大会
会议内容 ▼▲
- 1.To elect four (4) directors to our Board of Directors, to serve until the next annual meeting and until their successors are duly elected and qualified;
2.To ratify the appointment of Tanner LLC as the independent registered public accounting firm of Lipocine for the year ending December 31, 2021;
3.To adopt, on an advisory basis, a non-binding resolution approving the compensation of the Company’s named executive officers, as described in the Proxy Statement under “Executive Compensation”;
4.To approve an amendment to the Amended and Restated Certificate of Incorporation of the Company to increase the number of authorized shares of common stock from 100,000,000 to 250,000,000 shares;
5.To approve an amendment and restatement of our Fourth Amended and Restated 2014 Stock and Incentive Plan to (I) increase the annual individual award limits thereunder from 400,000 shares to 1,000,000 shares; and (II) clarify plan language relating to the application of annual limits under the plan:
6.To conduct any other business properly brought before the Annual Meeting and any adjournment or postponement thereof.
|
| 2020-04-28 |
股东大会：
将于2020-06-10召开股东大会
会议内容 ▼▲
- 1.To elect five (5) directors to our Board of Directors, to serve until the next annual meeting and until their successors are duly elected and qualified
2.To ratify the appointment of Tanner LLC as the independent registered public accounting firm of Lipocine for the year ending December 31, 2020;
3.To adopt, on an advisory basis, a non-binding resolution approving the compensation of the Company’s named executive officers, as described in the Proxy Statement under “Executive Compensation”;
4.To consider one stockholder proposal, if properly presented at the Annual Meeting, to provide for director election by the affirmative vote of the majority of votes cast at an annual meeting of stockholders in uncontested elections;
5.To approve an amendment and restatement of our Third Amended and Restated 2014 Stock and Incentive Plan to (i) increase the authorized number of shares of common stock of the Company issuable under all awards granted under such plan from 3,221,906 to 5,721,906, and (ii) update certain plan provisions regarding tax treatment to make them consistent with changes that were made to section 162(m) of the Internal Revenue Code under the Tax Cuts and Jobs Act;
6.To conduct any other business properly brought before the Annual Meeting and any adjournment or postponement thereof.
|
| 2019-04-30 |
股东大会：
将于2019-06-12召开股东大会
会议内容 ▼▲
- 1.To elect five (5) directors to our Board of Directors, to serve until the next annual meeting and until their successors are duly elected and qualified;
2.To ratify the appointment of Tanner LLC as the independent registered public accounting firm of Lipocine for the year ending December 31, 2019;
3.To adopt, on an advisory basis, a non-binding resolution approving the compensation of the Company’s named executive officers, as described in the Proxy Statement under “Executive Compensation”;
4.To consider one stockholder proposal, if properly presented at the Annual Meeting, to provide for director election by the affirmative vote of the majority of votes cast at an annual meeting of stockholders in uncontested elections;
5.To conduct any other business properly brought before the 2019 Annual Meeting and any adjournment or postponement thereof.
|
| 2018-04-27 |
股东大会：
将于2018-06-13召开股东大会
会议内容 ▼▲
- 1.To elect the five (5) directors to our Board of Directors, to serve until the next annual meeting and until their successors are duly elected and qualified;
2.To ratify the appointment of KPMG LLP as the independent registered public accounting firm of Lipocine for the year ended December 31, 2018;
3.To adopt, on an advisory basis, a non-binding resolution approving the compensation of the Company’s named executive officers, as described in the Proxy Statement under “Executive Compensation”;
4.To vote, on an advisory basis, on the frequency of the advisory vote to approve the compensation of the Company’s named executive officers;
5.To approve an amendment and restatement of our Second Amended and Restated 2014 Stock and Incentive Plan to increase the authorized number of shares of common stock of the Company issuable under all awards granted under such plan from 2,471,906 to 3,221,906;
6.To conduct any other business properly brought before the 2018 Annual Meeting and any adjournment or postponement thereof.
|
| 2017-04-28 |
股东大会：
将于2017-06-13召开股东大会
会议内容 ▼▲
- 1.ELECTION OF DIRECTORS. To elect the five (5) directors named in the attached proxy statement;
2.RATIFICATION OF AUDITORS. To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the year ended December 31, 2017;
3.ANY OTHER BUSINESS that may properly come before the Annual Meeting or any adjournments or postponements thereof.
|
| 2016-04-29 |
股东大会：
将于2016-06-14召开股东大会
会议内容 ▼▲
- 1.ELECTION OF DIRECTORS. To elect the five (5) directors named in the attached proxy statement;
2.AMENDMENT AND RESTATEMENT OF THE COMPANY’S AMENDED AND RESTATED 2014 STOCK AND INCENTIVE PLAN. To approve an amendment and restatement of our Amended and Restated 2014 Stock and Incentive Plan to increase the authorized number of shares of common stock of the Company issuable under all awards granted under such plan from 1,271,906 to 2,471,906;
3.RATIFICATION OF AUDITORS. To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the year ended December 31, 2016;
4.ANY OTHER BUSINESS that may properly come before the Annual Meeting or any adjournments or postponements thereof.
|